Oroxylin A exerts anticancer effects on human ovarian cancer cells via the PPARγ‑dependent reversal of the progesterone receptor membrane component 1/2 expression profile
Ovarian cancer is the most lethal gynecological cancer worldwide. To date, the therapeutic approaches available for the treatment of ovarian cancer are still very limited. The present study first demonstrated that the Chinese herb, Oroxylin A, exerts inhibitory effects on both the migratory ability...
Gespeichert in:
| Veröffentlicht in: | Oncology reports 2020-04, Vol.43 (4), p.1309-1318 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1318 |
|---|---|
| container_issue | 4 |
| container_start_page | 1309 |
| container_title | Oncology reports |
| container_volume | 43 |
| creator | Shen, Jian-Jiang Zhu, Xiao-Fei Xu, Juan Wang, Zhi-Fei Gu, Wan-Jian Chen, Yun |
| description | Ovarian cancer is the most lethal gynecological cancer worldwide. To date, the therapeutic approaches available for the treatment of ovarian cancer are still very limited. The present study first demonstrated that the Chinese herb, Oroxylin A, exerts inhibitory effects on both the migratory ability and viability of ovarian cancer cells. Notably, the inhibitory effects of the drug occurred in a dose‑dependent manner. Oroxylin A only inhibited cell migration at the lower dose, whereas it induced early or late apoptosis at the middle or higher doses, respectively. Mechanistically, Oroxylin A increased peroxisome proliferator‑activated receptor gamma (PPARγ) expression and altered the expression profile of progesterone receptor membrane component (PGRMC)1/2. Notably, PPARγ was revealed to play a central role in Oroxylin A‑mediated anticancer activity. The silencing of PPARγ significantly abrogated Oroxylin A‑induced apoptotic cell death and restored the expression profile of the PGRMC1/2 family in ovarian cancer cells. Collectively, the present study revealed that Oroxylin A exerted marked anticancer effects against ovarian cancer in vitro. Thus, Oroxylin A may have potential for use as a complementary therapy in the treatment of ovarian cancer. |
| doi_str_mv | 10.3892/or.2020.7509 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2394250503</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2394250503</sourcerecordid><originalsourceid>FETCH-LOGICAL-c357t-28113d0a7286ff6ccdce448ce5d9e7eaab57d4e5e35763d3519e1bd536da58153</originalsourceid><addsrcrecordid>eNpdkU1u1TAQxy0EoqWwY40ssWFBXv0Rx8nyqeJLqtQKgcQu8rMnNFVih3Hy1O64Qm_QE7DhBhyAQ3AS5tEHC-TFWDO_mfmP_ow9lWKl60YdJ1wpocTKGtHcY4fSNrJQpZb36S-ULLQ2nw7Yo5wvhVBWVM1DdqAVPdtUh-zbGaar66GPP27XHK4A58xdnHvvogfk0HXgKZUiv1hGF3naOuwp7usehiHzbe_4fAH8_Hz9_uf3X19vAkwQA8SZI2wBsxt46v4gE6bPkGfAFIGKHqY5IR9h3KCjjE_jRBVqlMeK9EwIOfe0nfq6foDH7EHnhgxP9vGIfXz96sPJ2-L07M27k_Vp4bWxc6FqKXUQzqq66rrK--ChLGsPJjRgwbmNsaEEA0RXOmgjG5CbYHQVnKml0Ufsxd1c2vtlIcHt2OfdsSQyLblVuimVEUZoQp__h16mBSOpI8qSG6KyNVEv7yiPKWeErp2wHx1et1K0Ox_bhO3Ox3bnI-HP9kOXzQjhH_zXOP0bV-qelA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2377910678</pqid></control><display><type>article</type><title>Oroxylin A exerts anticancer effects on human ovarian cancer cells via the PPARγ‑dependent reversal of the progesterone receptor membrane component 1/2 expression profile</title><source>MEDLINE</source><source>Alma/SFX Local Collection</source><source>EZB Electronic Journals Library</source><creator>Shen, Jian-Jiang ; Zhu, Xiao-Fei ; Xu, Juan ; Wang, Zhi-Fei ; Gu, Wan-Jian ; Chen, Yun</creator><creatorcontrib>Shen, Jian-Jiang ; Zhu, Xiao-Fei ; Xu, Juan ; Wang, Zhi-Fei ; Gu, Wan-Jian ; Chen, Yun</creatorcontrib><description>Ovarian cancer is the most lethal gynecological cancer worldwide. To date, the therapeutic approaches available for the treatment of ovarian cancer are still very limited. The present study first demonstrated that the Chinese herb, Oroxylin A, exerts inhibitory effects on both the migratory ability and viability of ovarian cancer cells. Notably, the inhibitory effects of the drug occurred in a dose‑dependent manner. Oroxylin A only inhibited cell migration at the lower dose, whereas it induced early or late apoptosis at the middle or higher doses, respectively. Mechanistically, Oroxylin A increased peroxisome proliferator‑activated receptor gamma (PPARγ) expression and altered the expression profile of progesterone receptor membrane component (PGRMC)1/2. Notably, PPARγ was revealed to play a central role in Oroxylin A‑mediated anticancer activity. The silencing of PPARγ significantly abrogated Oroxylin A‑induced apoptotic cell death and restored the expression profile of the PGRMC1/2 family in ovarian cancer cells. Collectively, the present study revealed that Oroxylin A exerted marked anticancer effects against ovarian cancer in vitro. Thus, Oroxylin A may have potential for use as a complementary therapy in the treatment of ovarian cancer.</description><identifier>ISSN: 1021-335X</identifier><identifier>EISSN: 1791-2431</identifier><identifier>DOI: 10.3892/or.2020.7509</identifier><identifier>PMID: 32323796</identifier><language>eng</language><publisher>Greece: Spandidos Publications UK Ltd</publisher><subject>Apoptosis ; Cancer therapies ; Cell cycle ; Cell Line, Tumor ; Cell Movement ; Cell Proliferation ; Female ; Flavonoids - pharmacology ; Flow cytometry ; Gene expression ; Humans ; Leukemia ; Ligands ; Membrane Proteins - metabolism ; Ovarian cancer ; Ovarian Neoplasms - drug therapy ; Ovarian Neoplasms - metabolism ; Ovarian Neoplasms - pathology ; PPAR gamma - agonists ; Receptors, Progesterone - metabolism ; Signal Transduction</subject><ispartof>Oncology reports, 2020-04, Vol.43 (4), p.1309-1318</ispartof><rights>Copyright Spandidos Publications UK Ltd. 2020</rights><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c357t-28113d0a7286ff6ccdce448ce5d9e7eaab57d4e5e35763d3519e1bd536da58153</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32323796$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Shen, Jian-Jiang</creatorcontrib><creatorcontrib>Zhu, Xiao-Fei</creatorcontrib><creatorcontrib>Xu, Juan</creatorcontrib><creatorcontrib>Wang, Zhi-Fei</creatorcontrib><creatorcontrib>Gu, Wan-Jian</creatorcontrib><creatorcontrib>Chen, Yun</creatorcontrib><title>Oroxylin A exerts anticancer effects on human ovarian cancer cells via the PPARγ‑dependent reversal of the progesterone receptor membrane component 1/2 expression profile</title><title>Oncology reports</title><addtitle>Oncol Rep</addtitle><description>Ovarian cancer is the most lethal gynecological cancer worldwide. To date, the therapeutic approaches available for the treatment of ovarian cancer are still very limited. The present study first demonstrated that the Chinese herb, Oroxylin A, exerts inhibitory effects on both the migratory ability and viability of ovarian cancer cells. Notably, the inhibitory effects of the drug occurred in a dose‑dependent manner. Oroxylin A only inhibited cell migration at the lower dose, whereas it induced early or late apoptosis at the middle or higher doses, respectively. Mechanistically, Oroxylin A increased peroxisome proliferator‑activated receptor gamma (PPARγ) expression and altered the expression profile of progesterone receptor membrane component (PGRMC)1/2. Notably, PPARγ was revealed to play a central role in Oroxylin A‑mediated anticancer activity. The silencing of PPARγ significantly abrogated Oroxylin A‑induced apoptotic cell death and restored the expression profile of the PGRMC1/2 family in ovarian cancer cells. Collectively, the present study revealed that Oroxylin A exerted marked anticancer effects against ovarian cancer in vitro. Thus, Oroxylin A may have potential for use as a complementary therapy in the treatment of ovarian cancer.</description><subject>Apoptosis</subject><subject>Cancer therapies</subject><subject>Cell cycle</subject><subject>Cell Line, Tumor</subject><subject>Cell Movement</subject><subject>Cell Proliferation</subject><subject>Female</subject><subject>Flavonoids - pharmacology</subject><subject>Flow cytometry</subject><subject>Gene expression</subject><subject>Humans</subject><subject>Leukemia</subject><subject>Ligands</subject><subject>Membrane Proteins - metabolism</subject><subject>Ovarian cancer</subject><subject>Ovarian Neoplasms - drug therapy</subject><subject>Ovarian Neoplasms - metabolism</subject><subject>Ovarian Neoplasms - pathology</subject><subject>PPAR gamma - agonists</subject><subject>Receptors, Progesterone - metabolism</subject><subject>Signal Transduction</subject><issn>1021-335X</issn><issn>1791-2431</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNpdkU1u1TAQxy0EoqWwY40ssWFBXv0Rx8nyqeJLqtQKgcQu8rMnNFVih3Hy1O64Qm_QE7DhBhyAQ3AS5tEHC-TFWDO_mfmP_ow9lWKl60YdJ1wpocTKGtHcY4fSNrJQpZb36S-ULLQ2nw7Yo5wvhVBWVM1DdqAVPdtUh-zbGaar66GPP27XHK4A58xdnHvvogfk0HXgKZUiv1hGF3naOuwp7usehiHzbe_4fAH8_Hz9_uf3X19vAkwQA8SZI2wBsxt46v4gE6bPkGfAFIGKHqY5IR9h3KCjjE_jRBVqlMeK9EwIOfe0nfq6foDH7EHnhgxP9vGIfXz96sPJ2-L07M27k_Vp4bWxc6FqKXUQzqq66rrK--ChLGsPJjRgwbmNsaEEA0RXOmgjG5CbYHQVnKml0Ufsxd1c2vtlIcHt2OfdsSQyLblVuimVEUZoQp__h16mBSOpI8qSG6KyNVEv7yiPKWeErp2wHx1et1K0Ox_bhO3Ox3bnI-HP9kOXzQjhH_zXOP0bV-qelA</recordid><startdate>20200401</startdate><enddate>20200401</enddate><creator>Shen, Jian-Jiang</creator><creator>Zhu, Xiao-Fei</creator><creator>Xu, Juan</creator><creator>Wang, Zhi-Fei</creator><creator>Gu, Wan-Jian</creator><creator>Chen, Yun</creator><general>Spandidos Publications UK Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AN0</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>20200401</creationdate><title>Oroxylin A exerts anticancer effects on human ovarian cancer cells via the PPARγ‑dependent reversal of the progesterone receptor membrane component 1/2 expression profile</title><author>Shen, Jian-Jiang ; Zhu, Xiao-Fei ; Xu, Juan ; Wang, Zhi-Fei ; Gu, Wan-Jian ; Chen, Yun</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c357t-28113d0a7286ff6ccdce448ce5d9e7eaab57d4e5e35763d3519e1bd536da58153</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Apoptosis</topic><topic>Cancer therapies</topic><topic>Cell cycle</topic><topic>Cell Line, Tumor</topic><topic>Cell Movement</topic><topic>Cell Proliferation</topic><topic>Female</topic><topic>Flavonoids - pharmacology</topic><topic>Flow cytometry</topic><topic>Gene expression</topic><topic>Humans</topic><topic>Leukemia</topic><topic>Ligands</topic><topic>Membrane Proteins - metabolism</topic><topic>Ovarian cancer</topic><topic>Ovarian Neoplasms - drug therapy</topic><topic>Ovarian Neoplasms - metabolism</topic><topic>Ovarian Neoplasms - pathology</topic><topic>PPAR gamma - agonists</topic><topic>Receptors, Progesterone - metabolism</topic><topic>Signal Transduction</topic><toplevel>online_resources</toplevel><creatorcontrib>Shen, Jian-Jiang</creatorcontrib><creatorcontrib>Zhu, Xiao-Fei</creatorcontrib><creatorcontrib>Xu, Juan</creatorcontrib><creatorcontrib>Wang, Zhi-Fei</creatorcontrib><creatorcontrib>Gu, Wan-Jian</creatorcontrib><creatorcontrib>Chen, Yun</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>British Nursing Database</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>PML(ProQuest Medical Library)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Oncology reports</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Shen, Jian-Jiang</au><au>Zhu, Xiao-Fei</au><au>Xu, Juan</au><au>Wang, Zhi-Fei</au><au>Gu, Wan-Jian</au><au>Chen, Yun</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Oroxylin A exerts anticancer effects on human ovarian cancer cells via the PPARγ‑dependent reversal of the progesterone receptor membrane component 1/2 expression profile</atitle><jtitle>Oncology reports</jtitle><addtitle>Oncol Rep</addtitle><date>2020-04-01</date><risdate>2020</risdate><volume>43</volume><issue>4</issue><spage>1309</spage><epage>1318</epage><pages>1309-1318</pages><issn>1021-335X</issn><eissn>1791-2431</eissn><abstract>Ovarian cancer is the most lethal gynecological cancer worldwide. To date, the therapeutic approaches available for the treatment of ovarian cancer are still very limited. The present study first demonstrated that the Chinese herb, Oroxylin A, exerts inhibitory effects on both the migratory ability and viability of ovarian cancer cells. Notably, the inhibitory effects of the drug occurred in a dose‑dependent manner. Oroxylin A only inhibited cell migration at the lower dose, whereas it induced early or late apoptosis at the middle or higher doses, respectively. Mechanistically, Oroxylin A increased peroxisome proliferator‑activated receptor gamma (PPARγ) expression and altered the expression profile of progesterone receptor membrane component (PGRMC)1/2. Notably, PPARγ was revealed to play a central role in Oroxylin A‑mediated anticancer activity. The silencing of PPARγ significantly abrogated Oroxylin A‑induced apoptotic cell death and restored the expression profile of the PGRMC1/2 family in ovarian cancer cells. Collectively, the present study revealed that Oroxylin A exerted marked anticancer effects against ovarian cancer in vitro. Thus, Oroxylin A may have potential for use as a complementary therapy in the treatment of ovarian cancer.</abstract><cop>Greece</cop><pub>Spandidos Publications UK Ltd</pub><pmid>32323796</pmid><doi>10.3892/or.2020.7509</doi><tpages>10</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1021-335X |
| ispartof | Oncology reports, 2020-04, Vol.43 (4), p.1309-1318 |
| issn | 1021-335X 1791-2431 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2394250503 |
| source | MEDLINE; Alma/SFX Local Collection; EZB Electronic Journals Library |
| subjects | Apoptosis Cancer therapies Cell cycle Cell Line, Tumor Cell Movement Cell Proliferation Female Flavonoids - pharmacology Flow cytometry Gene expression Humans Leukemia Ligands Membrane Proteins - metabolism Ovarian cancer Ovarian Neoplasms - drug therapy Ovarian Neoplasms - metabolism Ovarian Neoplasms - pathology PPAR gamma - agonists Receptors, Progesterone - metabolism Signal Transduction |
| title | Oroxylin A exerts anticancer effects on human ovarian cancer cells via the PPARγ‑dependent reversal of the progesterone receptor membrane component 1/2 expression profile |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-03T14%3A41%3A30IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Oroxylin%C2%A0A%20exerts%20anticancer%20effects%20on%20human%20ovarian%20cancer%20cells%20via%20the%20PPAR%CE%B3%E2%80%91dependent%20reversal%20of%20the%20progesterone%20receptor%20membrane%20component%201/2%20expression%20profile&rft.jtitle=Oncology%20reports&rft.au=Shen,%20Jian-Jiang&rft.date=2020-04-01&rft.volume=43&rft.issue=4&rft.spage=1309&rft.epage=1318&rft.pages=1309-1318&rft.issn=1021-335X&rft.eissn=1791-2431&rft_id=info:doi/10.3892/or.2020.7509&rft_dat=%3Cproquest_cross%3E2394250503%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2377910678&rft_id=info:pmid/32323796&rfr_iscdi=true |